Skip to Main Content

Paper Details

Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling study.
Lancet Reg Health Am
2
2023
Author NameAffiliation
Renato D LopesDuke Clinical Research Institute, Duke University School of Medicine
  • 1 - 1

Datasets

Release 1.2